Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome.

STAT1, activated by both type I and type II IFN via JAK1/2, showed significantly elevated phosphorylation at Tyr701 and Ser727 in neutrophils from patients with AOSD when compared with healthy controls with higher levels in patients with MAS than in those without MAS, although the latter did not reach statistical significance ( supplemental Figure 3 A).

also in 111,027 other papers